Jul. 13 at 9:23 PM
$IFRX A thesis for a CSL Vifor partnership with InflaRx in the EU:
Full details: https://nobrainerbio.substack.com/i/193888312/july-13-2026
The highlights:
CSL/VFMCRP is walking away from a
$145M/year avacopan franchise after EMA recommended full EU revocation June 26, 2026 — on data integrity grounds, not just safety.
CSL built purpose-built European AAV commercial infrastructure for a C5aR1 mechanism — KOL relationships, reimbursement pathways, clinical networks — now sitting idle with no drug.
InflaRx has a Phase 3-ready vilobelimab AAV asset with two completed European Phase 2 studies, an existing EU regulatory approval (GOHIBIC for ARDS), and izicopan Phase 2 in AAV already planned.
The two-stage opportunity: vilobelimab now to fill the gap, izicopan when Phase 2 data matures — the oral-to-oral replacement that CSL's infrastructure was literally built for.
InflaRx responded four days after the CHMP announcement with a carefully worded PR — suggesting advance preparation, not surprise.
